Theriva Biologics, Inc. Logo

Theriva Biologics, Inc.

Develops systemic oncolytic virus therapies to selectively destroy difficult-to-treat cancers.

TOVX | US

Overview

Corporate Details

ISIN(s):
US87164U5083 (+1 more)
LEI:
Country:
United States of America
Address:
9605 MEDICAL CENTER DRIVE, 20850 ROCKVILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Theriva Biologics, Inc. is a clinical-stage immuno-oncology company developing a new class of oncolytic virus therapeutics. The company's platform engineers viruses for systemic delivery, designed to overcome the protective barriers of solid tumors and selectively destroy cancer cells. These developmental therapies are intended to treat a broad range of difficult-to-treat cancers and have the potential to be combined with or enhance current standard-of-care treatments. Theriva's lead candidates are being evaluated in clinical trials to address diseases in areas of high unmet medical need.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Theriva Biologics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Theriva Biologics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Theriva Biologics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea
311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea
063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America
CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America
CLNN
Climb Bio, Inc. Logo
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America
CLYM
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea
058820
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America
COCP

Talk to a Data Expert

Have a question? We'll get back to you promptly.